Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.sapharm.2021.08.008 | DOI Listing |
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
JMIR Res Protoc
January 2025
Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium.
Background: Young patients aged 16 to 25 years with type 1 diabetes (T1D) often encounter challenges related to deteriorating disease control and accelerated complications. Mobile apps have shown promise in enhancing self-care among youth with diabetes. However, inconsistent findings suggest that further evidence is necessary to confirm the effectiveness of app-based interventions.
View Article and Find Full Text PDFJ Occup Environ Hyg
January 2025
Center for Environmental Solutions and Emergency Response, United States Environmental Protection Agency, Cincinnati, Ohio.
Chemical release data are essential for performing chemical risk assessments to understand the potential exposures arising from industrial processes. Often, these data are unknown or unavailable and must be estimated. A case study of volatile organic compound releases during extrusion-based additive manufacturing is used here to explore the viability of various regression methods for predicting chemical releases to inform chemical assessments.
View Article and Find Full Text PDFJ Am Acad Orthop Surg Glob Res Rev
January 2025
Universidad Autónoma de Guadalajara, School of Medicine, Zapopan, Mexico.
Background: Physicians worldwide face the challenging task of improving patient satisfaction by reducing pain in injured patients. Currently, available therapeutic approaches provide only short-term relief of symptoms without addressing long-term satisfaction. This has led to exploring regenerative treatment options that can deliver better outcomes.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
Department of Epidemiology and Health Economics, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Purpose: To evaluate the cost utility of a 9-month supervised exercise program for patients with metastatic breast cancer (mBC), compared with control (usual care, supplemented with general activity advice and an activity tracker). Evidence on the cost-effectiveness of exercise for patients with mBC is essential for implementation in clinical practice and is currently lacking.
Methods: A cost-utility analysis was performed alongside the multinational PREFERABLE-EFFECT randomized controlled trial, conducted in 8 centers across Europe and Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!